| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
As a synthetic intermediate, (R)-2-Amino-2-(thiophen-3-yl)acetic acid has potential biological targets related to its thiophene-containing structure. The mechanism of action involves its interaction with specific molecular targets and pathways. Its antimicrobial activity may be attributed to its ability to disrupt bacterial cell membranes or inhibit essential enzymes. The antioxidant activity is likely due to its capacity to scavenge free radicals and reduce oxidative stress. The compound's chiral nature and the presence of both an amino group and a thiophene ring impart distinct chemical and biological properties. The compound does not have a defined pharmacological target in the classical sense, but its structure makes it valuable for studying interactions with biological systems.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of (R)-2-Amino-2-(thiophen-3-yl)acetic acid is evaluated through its performance as a synthetic building block and its potential biological activities. As a chiral amino acid derivative, it is used in the synthesis of peptides and bioactive compounds. The compound's unique structure imparts various biological activities, making it a subject of interest in medicinal chemistry and pharmacology. Typical assays might include antimicrobial activity testing, antioxidant activity assays, or enzyme inhibition studies depending on the research focus. No specific in vitro activity data are available for this compound as a standalone entity. |
| ln Vivo |
In vivo activity of (R)-2-Amino-2-(thiophen-3-yl)acetic acid has not been extensively characterized. The compound is primarily used as a research reagent and synthetic building block, not as a therapeutic agent. Any in vivo studies would involve the final peptide products incorporating this amino acid rather than the compound itself.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for (R)-2-Amino-2-(thiophen-3-yl)acetic acid involves standard organic synthesis and characterization procedures. A typical workflow: dissolve the compound in appropriate solvent, activate the carboxylic acid (if needed), and couple with other amino acid derivatives using standard coupling reagents such as HATU or HBTU. Characterize by NMR and MS. The compound's IUPAC name is (2R)-2-amino-2-thiophen-3-ylacetic acid. The compound's SMILES is C1=CSC=C1[C@H](C(=O)O)N.
|
| Cell Assay |
In vitro cell-based experimental workflows for (R)-2-Amino-2-(thiophen-3-yl)acetic acid may involve studying its antimicrobial or antioxidant activities. Cells are cultured in appropriate medium, treated with varying concentrations of the compound, and analyzed for cell viability, antimicrobial activity, or oxidative stress markers. However, such assays are not standard for this compound, as it is primarily a synthetic building block.
|
| Animal Protocol |
In vivo animal experiments are not applicable for (R)-2-Amino-2-(thiophen-3-yl)acetic acid. The compound is not intended for administration to animals as a therapeutic agent.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of (R)-2-Amino-2-(thiophen-3-yl)acetic acid have not been characterized. The compound is not a drug. No ADME data are available.
|
| Toxicity/Toxicokinetics |
The toxicological data for (R)-2-Amino-2-(thiophen-3-yl)acetic acid are limited. Standard laboratory safety practices should be followed. The compound is intended for research use only.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
(R)-2-Amino-2-(thiophen-3-yl)acetic acid is a chiral non-proteinogenic amino acid derivative featuring a thiophene ring. The compound is a glycine derivative and is used as a building block in medicinal chemistry and peptide synthesis. The (R)-enantiomer is of particular interest due to its potential biological activity. The compound is not a drug and has no clinical trials or approvals. The compound is for research use only.
|
| Molecular Formula |
C6H7NO2S
|
|---|---|
| Molecular Weight |
157.19
|
| Exact Mass |
157.019
|
| CAS # |
1194-86-1
|
| PubChem CID |
40520333
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
383.8±22.0 °C at 760 mmHg
|
| Melting Point |
218℃
|
| Flash Point |
185.9±22.3 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.660
|
| LogP |
0.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
10
|
| Complexity |
140
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CSC=C1[C@H](C(=O)O)N
|
| InChi Key |
BVGBBSAQOQTNGF-RXMQYKEDSA-N
|
| InChi Code |
InChI=1S/C6H7NO2S/c7-5(6(8)9)4-1-2-10-3-4/h1-3,5H,7H2,(H,8,9)/t5-/m1/s1
|
| Chemical Name |
(2R)-2-amino-2-thiophen-3-ylacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.3617 mL | 31.8086 mL | 63.6173 mL | |
| 5 mM | 1.2723 mL | 6.3617 mL | 12.7235 mL | |
| 10 mM | 0.6362 mL | 3.1809 mL | 6.3617 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
